Coronary Angioplasty (PCI) — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Coronary angioplasty — formally called percutaneous coronary intervention (PCI) — is a catheter-based procedure that uses a balloon-tipped catheter advanced through a peripheral artery under fluoroscopic (X-ray) guidance to open narrowed or blocked coronary arteries, restoring blood flow to the heart muscle. In virtually all cases, a metal scaffold called a stent is placed at the site of narrowing to maintain arterial patency after balloon dilation. Modern drug-eluting stents (DES) — metal platforms coated with antiproliferative drugs such as everolimus or zotarolimus — release their drug over 2–4 weeks, dramatically reducing in-stent restenosis rates to 5–10% at one year compared with 20–30% for bare-metal stents. PCI is the most common major cardiovascular procedure performed worldwide, with approximately 3.5 million procedures annually in Europe and North America. It was first performed by Andreas Grüntzig in Zurich in 1977 using a balloon-only technique; the addition of stenting, and subsequently drug-eluting stents, has progressively refined and expanded its application. Over one million PCI procedures are performed annually in the United States; the UK NHS performs approximately 100,000 each year, making it one of the most common invasive cardiac procedures globally.

Primary PCI (pPCI) — emergency angioplasty for STEMI (ST-elevation myocardial infarction) — is the gold-standard reperfusion strategy for acute heart attack when the procedure can be performed within 90 minutes of first medical contact ('door-to-balloon time'). Evidence demonstrates that pPCI reduces 30-day mortality from approximately 12–14% with fibrinolysis to 5–7%, and reduces stroke risk, making it the strongly preferred revascularisation strategy. For NSTEMI (non-ST-elevation MI) and unstable angina, early invasive angiography with PCI within 24–72 hours of admission is indicated in intermediate and high-risk patients according to GRACE score and troponin trajectory. For stable coronary artery disease, PCI is indicated when significant coronary stenosis (fractional flow reserve FFR ≤0.80 or iFR ≤0.89) causes limiting angina or evidence of large-territory ischaemia on functional imaging despite optimal medical therapy, particularly for single- or double-vessel disease. Multi-vessel coronary disease with complex anatomy or left main stem stenosis is typically referred for surgical revascularisation (CABG) based on SYNTAX score and Heart Team discussion, as CABG provides superior long-term outcomes in complex multivessel disease.

The patient lies on a fluoroscopy table in the cardiac catheterisation laboratory. The radial artery at the wrist (preferred — lower bleeding and complication rates, same-day discharge possible) or femoral artery in the groin is punctured under local anaesthesia using the Seldinger technique, and a vascular sheath is introduced. Anticoagulation (heparin or bivalirudin) and antiplatelet preloading (aspirin + P2Y12 inhibitor: ticagrelor or prasugrel for ACS, clopidogrel for elective PCI) are administered. A guiding catheter is advanced to the ostium of the target coronary artery under fluoroscopic guidance. A 0.014-inch coronary guidewire is manipulated across the coronary stenosis under real-time X-ray imaging. A balloon catheter is advanced over the guidewire and positioned at the stenosis; balloon inflation at 8–14 atmospheres pressure (using a manually controlled inflation device) compresses the atherosclerotic plaque and dilates the artery. One or more drug-eluting stents are then deployed — expanded at high pressure to appose fully against the arterial wall. Intravascular imaging with OCT (optical coherence tomography) or IVUS (intravascular ultrasound) is used in complex cases to optimise stent deployment. Post-dilatation ballooning is performed if under-expansion is detected. Total procedure time is 30–90 minutes for elective PCI; primary PCI can be completed in under 30 minutes in experienced centres.

Primary PCI for STEMI is dramatically life-saving: reducing 30-day mortality from 12–14% (fibrinolysis) to 5–7%, with lower rates of stroke, recurrent MI, and need for urgent repeat intervention. Angiographic success (TIMI 3 flow restored, final residual stenosis below 20%) is achieved in 95%+ of elective PCI cases at experienced centres. For stable angina, PCI achieves complete symptom elimination or significant reduction in angina frequency in 75–85% of patients, with superior immediate angina relief compared with medical therapy alone. Quality of life improvement, exercise capacity, and return to full activities are consistently superior in the first 1–3 years after PCI versus medical therapy. Drug-eluting stents have reduced angiographic restenosis (the main limitation of balloon-only PCI) to 5–10% at 12 months — most restenosis can be treated with a further PCI or drug-eluting balloon. The procedure avoids open-heart surgery and general anaesthesia, with same-day or next-day discharge for elective procedures, allowing rapid return to daily activities and work within 1–2 weeks.

Elective PCI carries a very low procedural mortality of less than 0.1–0.5% in experienced centres. Access-site complications — radial artery occlusion (1–5%), radial arterial spasm, haematoma, or pseudoaneurysm at the femoral site — are the most common adverse events. Contrast-induced nephropathy (CIN) affects 2–5% of patients, particularly those with pre-existing renal impairment; adequate hydration and minimising contrast volume are protective. Coronary dissection at the site of balloon dilation occurs in 2–5% and is managed by immediate stent placement. Coronary perforation (very rare, less than 0.5%) may require pericardiocentesis or emergency surgery. Stent thrombosis — acute occlusion of the stent by thrombus — occurs in less than 1% of cases but causes myocardial infarction in 50–70% of affected patients; it is prevented by uninterrupted dual antiplatelet therapy (DAPT). No-reflow phenomenon (failure to restore microvascular perfusion despite a patent epicardial artery) affects 5–10% of primary PCI cases and is managed with intracoronary adenosine, verapamil, or glycoprotein IIb/IIIa inhibitors. Radiation exposure from fluoroscopy is inherent but carefully minimised.

After radial access elective PCI, patients wear a wrist compression band for 2–4 hours; most are discharged on the same day or after a single overnight stay. After femoral access, 4–6 hours of bed rest with monitoring is required before ambulation. For primary PCI after STEMI, hospital stay is 2–3 days for ECG monitoring, haemodynamic observation, and initiation of secondary prevention therapies. Dual antiplatelet therapy (aspirin 75 mg daily lifelong + ticagrelor 90 mg twice daily or prasugrel 10 mg daily for 12 months post-ACS; clopidogrel 75 mg for 1–6 months post-elective PCI) must not be interrupted — premature discontinuation is the dominant preventable cause of stent thrombosis. Return to light activity within 2–3 days; driving after 1 week for elective PCI, 4 weeks after STEMI. Cardiac rehabilitation — structured exercise training and risk factor management — is strongly recommended after PCI for ACS and is associated with a 25% reduction in cardiovascular mortality at 5 years. Statin therapy, ACE inhibitor or ARB, and beta-blocker (post-MI) are prescribed for secondary prevention. Annual clinic review with ECG, echocardiography, and symptom assessment is standard.